Ocean Biomedical
Biotechnology, 55 Claverick St Rm 325, Providence, Rhode Island, 02903, United States, 11-50 Employees
Phone Number: 40********
Who is OCEAN BIOMEDICAL
Ocean Biomedical is a new-generation biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough m...
Read More
-
Headquarters: 55 Claverick St Rm 325, Providence, Rhode Island, 02903, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from OCEAN BIOMEDICAL
OCEAN BIOMEDICAL Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding OCEAN BIOMEDICAL
Answer: OCEAN BIOMEDICAL's headquarters are located at 55 Claverick St Rm 325, Providence, Rhode Island, 02903, United States
Answer: OCEAN BIOMEDICAL's phone number is 40********
Answer: OCEAN BIOMEDICAL's official website is https://oceanbiomedical.com
Answer: OCEAN BIOMEDICAL's revenue is $1 Million to $5 Million
Answer: OCEAN BIOMEDICAL's SIC: 8731
Answer: OCEAN BIOMEDICAL's NAICS: 541714
Answer: OCEAN BIOMEDICAL has 11-50 employees
Answer: OCEAN BIOMEDICAL is in Biotechnology
Answer: OCEAN BIOMEDICAL contact info: Phone number: 40******** Website: https://oceanbiomedical.com
Answer: Ocean Biomedical is a new-generation biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines. We're working to bring together the interdisciplinary expertise and resources required to develop a diverse portfolio of pharmaceutical inventions and technologies through preclinical, clinical, and commercial development. We aim to build a continuous pipeline of drug development opportunities through our relationships with universities and medical centers. Our current product candidates consist of preclinical programs each with potential for broad application in oncology, fibrosis, and the treatment and prevention of severe malaria. Our programs in oncology and fibrosis are based on discoveries of disease pathways and related drug targets emerging from pioneering work in the field of chitinase biology by our scientific co-founder, Jack A. Elias, M.D., a pulmonary specialist who was formerly the Dean of Medicine at Brown, and the Chairman of Medicine at Yale. In infectious disease, we are developing both therapeutic and vaccine candidates against malaria, a disease that kills 500,000 children and infects 200-300 million people globally each year. Our malaria program is built on the discovery by Jonathan Kurtis, M.D., of two novel malaria antigens, PfSEA-1 and PfGARP which have shown a significant reduction in malaria parasites under multiple levels of in-vitro and animal model testing. (press links below). Kurtis is the Chairman of Pathology and Laboratory Medicine at Brown and the founding director of the Center for International Health Research.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month